Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient InvestorsThe Motley Fool • 1h
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSemaZacks Investment Research • Monday
New research shows weight-loss drugs could be an effective option for children as young as 6 years oldWSJ • Monday
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027The Motley Fool • 11/15/26
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data showReuters • 11/14/26
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?The Motley Fool • 11/14/26
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness DayZacks Investment Research • 11/13/26
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routinePRNewsWire • 11/12/26
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?The Motley Fool • 11/12/26
ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea WinZacks Investment Research • 11/11/26
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?Zacks Investment Research • 11/11/26
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady24/7 Wall Street • 11/10/26